PMID- 24937942
OWN - NLM
STAT- MEDLINE
DCOM- 20140707
LR  - 20211021
IS  - 0350-199X (Print)
IS  - 1986-5961 (Electronic)
IS  - 0350-199X (Linking)
VI  - 68
IP  - 2
DP  - 2014
TI  - Platinum-based chemotherapy in recurrent high-grade glioma patients: 
      retrospective study.
PG  - 140-3
AB  - INTRODUCTION: To investigate the efficacy of platinum-based chemotherapy in 
      patients with recurrent high-grade glioma (HGG) who had received previous 
      alkylating line of chemotherapy. MATERIAL AND METHODS: Case notes of patients who 
      had received chemotherapy with carboplatin or cysplatin for recurrent HGG between 
      June 2006 and July 2012 were reviewed. Baseline characteristics and outcomes 
      after treatment were recorded. RESULTS: Forty-eight patients received 
      carboplatin/cysplatin as second line chemotherapy for recurrent HGG (grade III n 
      = 6; grade IV n = 42). The median number of cycles completed was 4. Fifteen 
      patients (28%) had at least minor response, 22 (49%) had stable disease and 11 
      (23%) had progressive disease. Six month progression-free survival was 30% (52% 
      in patients with grade III glioma and 18% in patients with grade IV glioma). The 
      median time to disease progression from the first treatment with platinum drug 
      was 3.2 months. The median survival was 8 months (10 months for patients with 
      grade III glioma and 7 months for patients with grade IV glioma). Among patients 
      with either stable disease or a partial response, the median survival was 12 
      months compared with 3 months in patients with progressive disease. No survival 
      or response rate differences were noted regarding the type of previous 
      chemotherapy, nitrosoureas or temozolomide. CONCLUSIONS: Single-agent 
      carboplatin/cysplatin has modest activity in patients with recurrent HGG 
      previously treated with one line of chemotherapy, nitrosoureas or temozolomide. 
      Despite the improvement of median survival of patients achieving stable disease 
      or a partial response to treatment, more effective regimens are required for this 
      patient population.
FAU - Roci, Ermir
AU  - Roci E
FAU - Cakani, Bujar
AU  - Cakani B
FAU - Brace, Gramoz
AU  - Brace G
FAU - Bushati, Teona
AU  - Bushati T
FAU - Rroji, Arben
AU  - Rroji A
FAU - Petrela, Mentor
AU  - Petrela M
FAU - Kaloshi, Gentian
AU  - Kaloshi G
LA  - eng
PT  - Journal Article
PL  - Bosnia and Herzegovina
TA  - Med Arch
JT  - Medical archives (Sarajevo, Bosnia and Herzegovina)
JID - 101635337
RN  - 0 (Antineoplastic Agents)
RN  - BG3F62OND5 (Carboplatin)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*therapeutic use
MH  - Biopsy
MH  - Brain Neoplasms/*drug therapy/pathology
MH  - Carboplatin/*therapeutic use
MH  - Cisplatin/*therapeutic use
MH  - Disease Progression
MH  - Female
MH  - Glioma/*drug therapy/pathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Recurrence, Local/*drug therapy/pathology
MH  - Neoplasm Staging
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Treatment Outcome
PMC - PMC4272495
COIS- CONFLICT OF INTEREST: NONE DECLARED
EDAT- 2014/06/19 06:00
MHDA- 2014/07/08 06:00
PMCR- 2014/04/01
CRDT- 2014/06/19 06:00
PHST- 2014/06/19 06:00 [entrez]
PHST- 2014/06/19 06:00 [pubmed]
PHST- 2014/07/08 06:00 [medline]
PHST- 2014/04/01 00:00 [pmc-release]
AID - MA-68-140 [pii]
AID - 10.5455/medarh.2014.68.140-143 [doi]
PST - ppublish
SO  - Med Arch. 2014;68(2):140-3. doi: 10.5455/medarh.2014.68.140-143.